MAIA Biotechnology Reports Over 2-Year Survival In Phase 2 THIO-101 NSCLC Trial;

MAIA Biotechnology, Inc. (NYSE: MAIA) announced positive results from its Phase 2 THIO-101 clinical trial for non-small cell lung cancer (NSCLC), reporting over two years of overall survival for eight patients treated with ateganosine and cemiplimab. Notably, one patient in third-line therapy survived 33 months, significantly exceeding the expected survival of 5.8 months for this heavily pre-treated group. Additionally, four patients in second-line therapy achieved over 30 months of survival, compared to the standard of care's documented 10.5 months. The results were presented at the European Lung Cancer Congress 2026 in Copenhagen.